IRIX Form 4: CFO Romeo Dizon Purchases 625 Shares for $1.34

Rhea-AI Filing Summary

Romeo R. Dizon, Chief Financial Officer of Iridex Corp (IRIX), reported a purchase of 625 shares of the company's common stock on 09/02/2025 at a price of $1.34 per share, increasing his beneficial ownership to 53,000 shares. The Form 4 was signed by an attorney-in-fact on 09/03/2025. The filing documents a routine insider purchase by a named officer and identifies no derivative transactions or additional disclosures.

Positive

• Officer purchase reported: Chief Financial Officer Romeo R. Dizon purchased 625 shares, indicating insider buying activity.
• Clear disclosure: Form 4 lists transaction date, price ($1.34), and updated beneficial ownership (53,000 shares).
• Proper execution: Filing signed by attorney-in-fact, providing the required signature and date (09/03/2025).

Negative

• None.

Insights

Financial Analyst

TL;DR: A routine officer purchase of 625 shares at $1.34 modestly increases insider ownership to 53,000 shares.

This transaction is small in absolute size and appears to be a personal purchase by the CFO rather than part of a disclosed plan. It does not include derivative activity or other notable changes to compensation or control. For investors, the filing confirms insider buying but is unlikely to be material to valuation given the modest size relative to a public company's outstanding shares.

Corporate Governance Expert

TL;DR: Compliance appears proper; Form 4 timely reports an officer purchase with attorney-in-fact signature.

The Form 4 contains the required details: reporting person, relationship (CFO), transaction date, code 'P' indicating purchase, number of shares, price, and post-transaction beneficial ownership. The signature block shows an attorney-in-fact executed the filing on 09/03/2025. There are no indications of late reporting or unusual arrangements in the disclosed content.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dizon Romeo R

(Last) (First) (Middle)

1212 TERRA BELLA AVENUE

(Street)

MOUNTAIN VIEW CA 94043

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRIDEX CORP [ IRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		P		625	A	$1.34	53,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Nilo De Castro, Attorney-in-fact for Romeo R. Dizon	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did IRIDEX (IRIX) insider Romeo R. Dizon report on Form 4?

He reported purchasing 625 shares of common stock on 09/02/2025 at $1.34 per share, increasing his beneficial ownership to 53,000 shares.

When was the Form 4 transaction executed and filed for IRIX?

Transaction date: 09/02/2025. Form signed: 09/03/2025 by an attorney-in-fact for Romeo R. Dizon.

What transaction code is used on the IRIX Form 4 and what does it indicate?

Code 'P' is used on the Form 4, indicating a purchase of securities.

Does the Form 4 for IRIDEX disclose any derivative transactions?

No. Table II for derivative securities contains no entries in the provided filing.

What is Romeo R. Dizon's role at IRIDEX as listed on the Form 4?

He is listed as the Chief Financial Officer and the Form identifies him as an officer of the issuer.